Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
ALK-Abelló (CPSE:ALK B) has drawn investor attention after reporting full year 2025 results, issuing fresh 2026 guidance and confirming a leadership change in R&D tied to its Allergy+ strategy.
See our latest analysis for ALK-Abelló.
The latest earnings, 2026 guidance and R&D leadership change appear to have shifted sentiment in the short term, with a 1 day share price return of 4.95% and shorter term momentum contrasting with a 1 year total shareholder return of 43.96% and 3 year total shareholder return of 106.95%. This suggests longer term strength, while recent 90 day share price returns have been softer.
If this Allergy+ update has you thinking about where else growth stories might emerge, it could be a good moment to scan our 113 healthcare AI stocks as potential next ideas to research.
With the shares up strongly over 1 and 3 years and the price sitting about 11% below one intrinsic estimate and 16% below analyst targets, investors may ask whether there is still a buying opportunity here or whether any potential future growth is already reflected in the price.
With ALK-Abelló last closing at DKK220.4 against a narrative fair value of DKK255, the widely followed view sees upside that the current price has not fully reflected yet.
The rapid expansion of ALK’s dedicated pediatric sales force in North America and strategic partnerships (e.g., ARS Pharma) are improving commercial reach and penetration, which, combined with broadening approval for pediatric use, should accelerate new patient growth and increase the volume of high-margin tablet sales.
Curious what sits behind that DKK255 fair value? Revenue curves, margin uplift and a future earnings multiple all interact in a tight set of projections. The key moving parts are more complex than simple top line growth. If you want to see how those assumptions stack up over the next few years, the full narrative lays it all out.
Result: Fair Value of DKK255 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, the story could change quickly if new products like EURneffy or pediatric tablets see slower uptake than analysts expect, or if R&D and capacity spending runs ahead of sales.
